The U.S. Food and Drug Administration (FDA) has issued a warning letter to Fresenius Medical Care's manufacturing arm after an inspection at its Ogden, Utah facility uncovered serious compliance failures. The letter, sent Tuesday to CEO Helen Giza, details violations that could put patients at risk of life-threatening infections.
The trouble started with a March 2026 inspection that found the plant had committed major Current Good Manufacturing Practice violations. According to the FDA, this means the finished pharmaceutical products made there are considered adulterated under the Federal Food, Drug, and Cosmetic Act. That's a strong statement, and the details behind it are worth unpacking.
Leaking Dialysis Bags and Missed Red Flags
The core issue revolves around Delflex Peritoneal Dialysis Solution, a sterile product used in a treatment that filters waste from the blood when kidneys fail. The FDA says the facility failed to thoroughly investigate customer complaints about leaking bags. In total, the plant received 35 complaints covering 156 leaking units, all linked to printing defects.
Here's where it gets concerning: internal risk protocols at Fresenius classify peritonitis, an infection of the abdominal lining, as a severe hazard. But the company categorized these leaks as low-severity property damage and avoided immediate recalls. That's a mismatch between the actual risk and the company's response. The FDA points out that non-sterile solutions can expose patients to life-threatening infections, especially because the dextrose in the solution actually helps microbes grow faster.
Fresenius did eventually issue voluntary recalls in April 2026, but only after the federal inspection had already happened. The timing suggests the recalls were a reaction to regulatory pressure rather than proactive patient safety.
Visual Inspection Gaps
The FDA also flagged the facility's visual inspection program. The plant was supposed to verify that sterile injectable products remained free of visible particles, but the program had a critical flaw: the qualification kits used to test inspectors didn't include representative particulate sizes. Specifically, they missed the 100-to-150 micron range, which is exactly the size range needed to adequately challenge whether staff could actually spot particles. If inspectors can't reliably detect particles, there's no way to ensure the products are truly clean.
Beyond that, the agency cited the facility for failing to establish adequate written procedures for process controls. That's a foundational issue, because without proper documentation and procedures, it's hard to maintain consistent quality.
What Happens Next
The FDA is requiring Fresenius to bring in an independent expert to conduct a full six-system audit, which covers everything from quality systems to facilities and equipment. The company also needs to overhaul its quality unit oversight and submit comprehensive remediation plans addressing process capability, root cause analyses, and manufacturing line controls.
The warning is clear: if Fresenius doesn't fix these issues promptly, the FDA could take enforcement actions. That might include product seizures, court injunctions, or withholding export certificates and new drug approvals. For a company that relies on regulatory approvals to operate, that's a serious threat.
Investors seem to be taking the news in stride, at least for now. Fresenius Medical Care shares were up 0.76% at $22.64 at the time of publication on Friday, according to market data. But the long-term impact will depend on how quickly the company can address these compliance failures and restore confidence in its manufacturing processes.
For patients who depend on dialysis products, this is a reminder of why regulatory oversight matters. The FDA's job is to catch these issues before they cause harm, and in this case, the agency is making it clear that Fresenius needs to do better.
